Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
about
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceA novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapyDynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cellsIdentification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavirRecent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesStructure and function of the human breast cancer resistance protein (BCRP/ABCG2).In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.Synthesis and quantitative structure-activity relationships of selective BCRP inhibitors.Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cellsBCRP/ABCG2 in the placenta: expression, function and regulation.A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasoundIn vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity.Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicityTransport processes of radiopharmaceuticals and -modulators.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.Design of inhibitors of BCRP/ABCG2.The importance of drug transporters in human pluripotent stem cells and in early tissue differentiation.Scaffold identification of a new class of potent and selective BCRP inhibitors.ABCG2/BCRP: Specific and Nonspecific Modulators.Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).Aurones as modulators of ABCG2 and ABCB1: synthesis and structure-activity relationships.5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.
P2860
Q26865927-FBB9D739-53DD-4FD4-A66B-45729C81859AQ28475529-61ACF9C1-F164-4F50-B4AA-CC2854B5BCDFQ28476445-9867BD11-1650-4CA8-8B10-022694C95A55Q33476723-1EB663DD-BE8D-4582-84FD-4A5B7AE954E2Q33547790-A6127C9E-39BD-4F6C-A82B-FB1ACB253697Q33611816-5951A606-AC86-4925-BACC-CD1938C82CC1Q33730375-6A872EE2-3372-4C0F-AC20-E9EFA8B5B8D3Q34176588-4698D053-7C8C-4F1B-9AAE-329D48EAD927Q34211108-E92246B1-3161-4E5B-8C4C-BCED4E2CF82CQ34476243-791EB242-49FC-4CBA-9B2A-6A626936BB6DQ34581006-A14F3500-A2DE-4DF1-91B9-CD29646A2BC6Q35128711-C5B8B1F3-3BF8-4C3E-B9C0-F2A77BF35C2FQ36593505-E4261CF3-004B-4385-8AB7-BE296AE24A29Q36629578-7D061857-B28D-411A-8F7D-53757B105115Q36685504-B55AAA29-CD93-4CAC-BA32-0DCB34E70FFBQ37070476-62C5B6DE-59C7-4B84-9530-D3906351B61CQ37221083-255A10DD-63FB-4D45-B49F-C4B1847727EBQ37698421-75556F58-0E8B-4C46-BD8B-3CEBE9A73C38Q37885468-BB6202B5-640D-4BBE-9B26-8A15907E375CQ38023238-623CDF18-87EA-4896-B805-608AD069AE48Q38570549-E818C982-AD2E-4C10-97B9-767E649F7B50Q38642449-18434A3B-36E8-402B-86ED-F966B42F6F29Q38904223-E0131F48-091A-4291-8F8D-26608CB1DEEBQ39049159-B28D70CB-DBD3-40EF-A013-E29B4E75D257Q39051270-06DDFBD4-54B8-4CA7-B806-C45EAF30D488Q39596096-48BA88A7-32FF-467A-92C6-1EF8FF3A00E1Q39600534-A18864CA-84BE-4035-A7F7-9B850F2D0A16Q51170112-65D76137-CB60-4A30-8A55-93FF6BD25ED0
P2860
Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@ast
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@en
type
label
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@ast
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@en
prefLabel
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@ast
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@en
P2093
P1433
P1476
Inhibitors of cancer cell mult ...... sistance protein (BCRP/ABCG2).
@en
P2093
Abdelhakim Ahmed-Belkacem
Ahcéne Boumendjel
Alexandre Pozza
Attilio Di Pietro
José M Pérez-Victoria
Sira Macalou
P304
P356
10.1097/00001813-200603000-00001
P577
2006-03-01T00:00:00Z